Literature DB >> 19903697

Human platelet aggregation and degranulation is induced in vitro by L-thyroxine, but not by 3,5,3'-triiodo-L-thyronine or diiodothyropropionic acid (DITPA).

Shaymaa S Mousa1, Faith B Davis, Paul J Davis, Shaker A Mousa.   

Abstract

The endogenous thyroid hormones L-thyroxine (T(4)) and 3,5,3'-triiodo-L-thyronine (T(3)) induce angiogenesis via an endothelial cell iodothyronine receptor on integrin alphaVbeta3. This receptor also exists on platelets. Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog, also induce angiogenesis. Here we examined the effects of iodothyronines (L-T(4) vs L-T(3)) and analogs DITPA and GC-1 on human platelet function. Subthreshold aggregation of platelets obtained from healthy human donors was induced with collagen. Platelet activation (proaggregation) and adenosine triphosphate (ATP) secretion (degranulation) induced by L-T( 4), L-T(4)-agarose, L-T(3), DITPA, or GC-1 were determined simultaneously. Platelet aggregation and ATP secretion induced by a subthreshold level of collagen were enhanced 3-fold by either L-T(4) or L-T( 4)-agarose (0.01 micromol/L) as compared to control, whereas, L-T( 3), DITPA, or GC-1 had no effect under the same conditions. The platelet proaggregatory and degranulation effects of L-T(4) were blocked by the alphavbeta3 antagonist XT199 (0.1 micromol/ L) and by tetraiodothyroacetic acid (tetrac; 0.1 micromol/L). Tetrac inhibits binding of thyroid hormone analogs to the receptor on alphavbeta3 and lacks thyromimetic activity at this site; thus, the proaggregatory action of L-T(4) likely involves the cell surface receptor on integrin alphavbeta3. The thyroid hormone receptor (TR) on human platelets but not endothelial cells distinguishes among iodothyronines, reflecting quantitative differences in integrin sites on endothelial cells and platelets or qualitative differences in the phospholipids/protein microenvironment of endothelial and platelet membranes that can affect integrin function. Additional studies in different populations with larger sample sizes are warranted to determine the impact of the current findings on clinical interventions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903697     DOI: 10.1177/1076029609348315

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  10 in total

Review 1.  Nongenomic actions of thyroid hormone.

Authors:  Paul J Davis; Fernando Goglia; Jack L Leonard
Journal:  Nat Rev Endocrinol       Date:  2015-12-15       Impact factor: 43.330

2.  Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles.

Authors:  Murat Yalcin; Hung-Yun Lin; Thangirala Sudha; Dhruba J Bharali; Ran Meng; Heng-Yuan Tang; Faith B Davis; Steven C Stain; Paul J Davis; Shaker A Mousa
Journal:  Horm Cancer       Date:  2013-02-28       Impact factor: 3.869

Review 3.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

Review 4.  Platelet ATP, Thyroid Hormone Receptor on Integrin αvβ3 and Cancer Metastasis.

Authors:  Paul J Davis; Shaker A Mousa; Geraldine P Schechter; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2019-12-14       Impact factor: 3.869

Review 5.  Small molecule hormone or hormone-like ligands of integrin αVβ3: implications for cancer cell behavior.

Authors:  Paul J Davis; Shaker A Mousa; Vivian Cody; Heng-Yuan Tang; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2013-08-14       Impact factor: 3.869

6.  Plasma-Based Proteomics Profiling of Patients with Hyperthyroidism after Antithyroid Treatment.

Authors:  Afshan Masood; Hicham Benabdelkamel; Aishah A Ekhzaimy; Assim A Alfadda
Journal:  Molecules       Date:  2020-06-19       Impact factor: 4.411

7.  Fluorinated Analog NMR s of Organosulfur Compounds from Garlic (Allium sativum): Synthesis, Chemistry and Anti-Angiogenesis and Antithrombotic Studies.

Authors:  Eric Block; Benjamin Bechand; Sivaji Gundala; Abith Vattekkatte; Kai Wang; Shaymaa S Mousa; Kavitha Godugu; Murat Yalcin; Shaker A Mousa
Journal:  Molecules       Date:  2017-11-28       Impact factor: 4.411

8.  Thyrotrophin and thyroxine support immune homeostasis in humans.

Authors:  Martin Jaeger; Yvette J E Sloot; Rob Ter Horst; Xiaojing Chu; Hans J P M Koenen; Valerie A C M Koeken; Simone J C F M Moorlag; Charlotte J de Bree; Vera P Mourits; Heidi Lemmers; Helga Dijkstra; Marco Medici; Antonius E van Herwaarden; Irma Joosten; Leo A B Joosten; Yang Li; Johannes W A Smit; Mihai G Netea; Romana T Netea-Maier
Journal:  Immunology       Date:  2021-02-07       Impact factor: 7.397

9.  Thyroid hormones and platelet activation in COVID-19 patients.

Authors:  O Gandini; C Lubrano; E Colonnello; A Criniti; E Lorusso; M Curreli; M Santulli; A Angeloni; L Gnessi
Journal:  J Endocrinol Invest       Date:  2022-09-05       Impact factor: 5.467

10.  Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management.

Authors:  Marwa S Hamza; Shaker A Mousa
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.